Cargando…
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disea...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909825/ https://www.ncbi.nlm.nih.gov/pubmed/31866818 http://dx.doi.org/10.3389/fnins.2019.01310 |
_version_ | 1783479003804336128 |
---|---|
author | Mejzini, Rita Flynn, Loren L. Pitout, Ianthe L. Fletcher, Sue Wilton, Steve D. Akkari, P. Anthony |
author_facet | Mejzini, Rita Flynn, Loren L. Pitout, Ianthe L. Fletcher, Sue Wilton, Steve D. Akkari, P. Anthony |
author_sort | Mejzini, Rita |
collection | PubMed |
description | The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disease-modifying genes identified, etiology remains unexplained and treatment options remain limited for the majority of ALS patients. Various factors have contributed to the slow progress in understanding and developing therapeutics for this disease. Here, we review the genetic basis of ALS, highlighting factors that have contributed to the elusiveness of genetic heritability. The most commonly mutated ALS-linked genes are reviewed with an emphasis on disease-causing mechanisms. The cellular processes involved in ALS pathogenesis are discussed, with evidence implicating their involvement in ALS summarized. Past and present therapeutic strategies and the benefits and limitations of the model systems available to ALS researchers are discussed with future directions for research that may lead to effective treatment strategies outlined. |
format | Online Article Text |
id | pubmed-6909825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69098252019-12-20 ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Mejzini, Rita Flynn, Loren L. Pitout, Ianthe L. Fletcher, Sue Wilton, Steve D. Akkari, P. Anthony Front Neurosci Neuroscience The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift as the number of genes associated with the disease risk and pathogenesis, and the cellular processes involved, continues to grow. Despite decades of intense research and over 50 potentially causative or disease-modifying genes identified, etiology remains unexplained and treatment options remain limited for the majority of ALS patients. Various factors have contributed to the slow progress in understanding and developing therapeutics for this disease. Here, we review the genetic basis of ALS, highlighting factors that have contributed to the elusiveness of genetic heritability. The most commonly mutated ALS-linked genes are reviewed with an emphasis on disease-causing mechanisms. The cellular processes involved in ALS pathogenesis are discussed, with evidence implicating their involvement in ALS summarized. Past and present therapeutic strategies and the benefits and limitations of the model systems available to ALS researchers are discussed with future directions for research that may lead to effective treatment strategies outlined. Frontiers Media S.A. 2019-12-06 /pmc/articles/PMC6909825/ /pubmed/31866818 http://dx.doi.org/10.3389/fnins.2019.01310 Text en Copyright © 2019 Mejzini, Flynn, Pitout, Fletcher, Wilton and Akkari. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Mejzini, Rita Flynn, Loren L. Pitout, Ianthe L. Fletcher, Sue Wilton, Steve D. Akkari, P. Anthony ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title_full | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title_fullStr | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title_full_unstemmed | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title_short | ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? |
title_sort | als genetics, mechanisms, and therapeutics: where are we now? |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909825/ https://www.ncbi.nlm.nih.gov/pubmed/31866818 http://dx.doi.org/10.3389/fnins.2019.01310 |
work_keys_str_mv | AT mejzinirita alsgeneticsmechanismsandtherapeuticswherearewenow AT flynnlorenl alsgeneticsmechanismsandtherapeuticswherearewenow AT pitoutianthel alsgeneticsmechanismsandtherapeuticswherearewenow AT fletchersue alsgeneticsmechanismsandtherapeuticswherearewenow AT wiltonsteved alsgeneticsmechanismsandtherapeuticswherearewenow AT akkaripanthony alsgeneticsmechanismsandtherapeuticswherearewenow |